Mesoblast Earnings Call: Ryoncil Momentum Meets Rising Costs

Mesoblast ((MESO)) has held its Q2 earnings call. Read on for the main highlights of the call.

Mesoblast’s latest earnings call struck a cautiously optimistic tone, with management highlighting a powerful commercial start for Ryoncil, exceptionally high margins and solid balance-sheet flexibility. At the same time, investors were reminded of rising operating costs, ongoing losses and a heavy reliance on one new therapy while the broader pipeline moves toward key regulatory milestones.

Ryoncil Launch Drives Revenue Surge

Ryoncil, launched in April 2025, has rapidly become Mesoblast’s growth engine, delivering $49 million in net product revenue in the first half of FY26. That contribution represented roughly 95.5% of total revenue of $51.3 million, with management noting sequential quarter-on-quarter growth since launch as uptake builds across U.S. transplant centers.

Exceptionally High Gross Margins Support Economics

The company reported a gross margin of 93% for the period, underscoring the attractive economics of its cell-therapy franchise. Gross profit excluding amortization reached about $44.2 million, giving Mesoblast ample room to reinvest in R&D and commercialization even as operating expenses climb with the scale-up.

Market Access and Commercial Momentum Strengthen

Commercial execution around Ryoncil is advancing quickly, with 49 treatment centers onboarded and 30 already listing the product on formulary. Payer coverage now spans more than 280 million lives with Medicaid access in all states, and a dedicated J‑code effective October 1 is expected to simplify billing while 13 hospitals leverage Optum Frontier to ease site-level financial burden.

Clear Penetration Targets in Pediatric GVHD

Management laid out defined market-share ambitions, targeting 20% penetration of the pediatric population within the first year post-launch. Internal models assume Ryoncil could ultimately reach about 40% peak share in pediatric graft-versus-host disease, although physician adoption patterns and real-world experience will determine how quickly those projections are realized.

Cash Reserves and New Credit Facility Bolster Runway

Mesoblast ended December 31, 2025 with $130 million in cash and secured a new $125 million non-dilutive credit facility. The company drew $75 million at closing and has an additional $50 million available through June 2026 under terms described as lower-cost, non-asset-cross-collateralized and repayable without prepayment penalties, providing flexibility to fund commercialization and late-stage trials.

Net Loss Narrows Despite Investment Cycle

For the first half of FY26, Mesoblast posted a net loss of $40.2 million, an improvement from a $48.0 million loss a year earlier despite the current investment phase. The comparative period benefited from a one-time $23 million inventory provision reversal, making the underlying progress in narrowing losses more notable even as the business absorbs launch and development spending.

Revascor Shows Strong LVAD Randomized Data

The company showcased compelling randomized data for Revascor in LVAD patients, with the LVAD II study and supportive LVAD I trial demonstrating statistically significant reductions in major bleeding events and related hospitalizations at six and twelve months. Management highlighted roughly a fivefold reduction in bleeding events over 12 months and evidence that the therapy mitigated right-heart-failure-related mortality versus controls.

Regulatory Pivot Toward Full BLA for Revascor

Building on the LVAD data and orphan-drug status, Mesoblast is shifting from an accelerated pathway to a full biologics license application in right-heart failure associated with LVAD support. The company aims to file the BLA next quarter, subject to completing required CMC and potency work, positioning Revascor as a potential second commercial pillar once approved.

Advancing Second-Generation rexlemestrocel-L in Back Pain

In chronic low back pain, first Phase III results in 404 patients underpinned FDA feedback that a 12-month pain reduction endpoint is approvable. A confirmatory Phase III enrolling 300 patients at about 40 U.S. sites is underway, with enrollment expected to complete in March or April 2026 and a data readout and possible BLA submission targeted for calendar 2027.

Manufacturing Scale-Up as a Strategic Priority

Management stressed ongoing work to build and diversify manufacturing capacity, aiming to support both Ryoncil’s growth and future launches like rexlemestrocel-L. Efforts include driving cost efficiencies and ensuring commercial readiness while advancing CMC and potency activities that are critical to regulatory filings and long-term supply reliability.

Rising R&D Spend Fuels Pipeline Progress

R&D expenses jumped to $46.2 million in the first half from $5.1 million a year earlier, with prior-year figures reduced by a $23 million inventory provision reversal. On an adjusted basis, R&D rose about 155% year-on-year, driven by adult GVHD studies, the back pain program, LVAD work, BLA preparation and associated manufacturing investments to support future approvals.

Higher SG&A Reflects Commercial Build-Out

Sales, general and administrative costs climbed to $28.5 million from $18.0 million, reflecting a roughly 58.3% increase as Mesoblast scales its commercial footprint. Spending is focused on sales and marketing infrastructure to support Ryoncil’s uptake, including field teams, market access initiatives and patient-support programs across the transplant ecosystem.

Operating Cash Use and Ongoing Losses Remain a Watchpoint

Despite improving trends, Mesoblast continues to burn cash, with operating cash flow usage of $30.3 million in the first half and a net loss still at $40.2 million. Management acknowledged that disciplined cash management and access to financing remain essential while the company transitions from a single-product revenue base to a more diversified portfolio.

Concentration Risk in a One-Product Revenue Model

Ryoncil accounted for roughly 95.5% of Mesoblast’s revenue in the period, underscoring reliance on a newly launched product for near-term financial performance. Until Revascor and rexlemestrocel-L progress to commercialization, the company remains exposed to any disruption in Ryoncil uptake, pricing, reimbursement or competitive dynamics in pediatric GVHD.

Pipeline Timelines and Regulatory Dependencies

Key value drivers are still several years out, with back pain Phase III data and a potential BLA not expected until 2027 and the Revascor BLA linked to completion of CMC and potency requirements. Management flagged active FDA discussions around labeling, including ischemic versus non-ischemic phenotypes, which could affect the scope of the cardiac indication at approval.

Debt Repayment and Optional Draws Shape Liquidity

While the new facility enhances flexibility, Mesoblast has begun repaying a subordinated royalty financing that it expects to fully retire by mid-2026, affecting future cash flows. The remaining $50 million under the new credit line is optional and available only through June 2026, making the timing of any additional draw an important strategic lever.

Education Efforts to Drive Adoption Curve

Management emphasized that sustained growth will depend on continued education of physicians and engagement of caregivers to drive earlier use of Ryoncil. Behavioral change in clinical practice can be slow, and the company acknowledged that inadequate awareness or comfort with the therapy could delay achieving its market-penetration targets despite strong access metrics.

Guidance Points to Growing Ryoncil Revenue and Lower Cash Burn

Looking ahead, Mesoblast guided full-year FY26 Ryoncil net revenue of $110 million to $120 million, up from $49 million booked in the first half. The company expects operating cash-flow usage to decline in the second half, supported by its $130 million cash balance, the $125 million credit facility and the planned full repayment of the subordinated royalty facility by mid-2026.

Mesoblast’s earnings call painted a picture of a company successfully transitioning into commercialization while still carrying the risks of an emerging biotech. Investors heard a story of strong early execution, high-margin revenue and a deep late-stage pipeline, balanced against rising costs, concentration on Ryoncil and multi-year regulatory timelines that will determine whether today’s momentum can translate into durable value.